Completed PHASE1 INTERVENTIONAL 8-arm NCT03709355

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers

Sponsor: Viriom

Conditions HIV-1-infection

Interventions Atorvastatin Clarithromycin Elpida® Levonorgestrel+Ethinylestradiol Omeprazole Rifabutin Rifampin

Updated 7 times since 2018 Last updated: Jan 10, 2022 Started: Nov 14, 2018 Primary completion: Sep 6, 2019 Completion: Sep 6, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03709355, this PHASE1 trial focuses on HIV-1-infection and remains completed. Sponsored by Viriom, it has been updated 7 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jan 2021 — Feb 2022 [monthly]

Unknown Status PHASE1

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Nov 2018 — Nov 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viriom

Data source: Viriom

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reutov, Russia